undamentalytics Newsletter
Sign in

Coya Therapeutics, Inc. balance sheet

At the end of fiscal 2025, Coya Therapeutics, Inc. had total assets of $50.0m, total liabilities of $6.9m and shareholders' equity of $43.0m. It held $46.8m in cash against $0 of debt: net cash of $46.8m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents633384743
Total current assets741445047
Total assets841445047
Accounts payable21211
Deferred revenue (current)—1111
Total current liabilities45464
Long-term debt13————
Total debt13—000
Total liabilities176574
Shareholders' equity−836404343
Net debt (negative = net cash)7−33−38−47−43
Shares outstanding10m—17m—23m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: ACRS vs COYAADAG vs COYAAPLM vs COYA

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Coya Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Coya Therapeutics, Inc.